Skip to main content
Year archive

PERCHERON THERAPEUTICS LIMITED — 2014 filings

All 60 regulatory filings released by PERCHERON THERAPEUTICS LIMITED (PER) in 2014, sourced directly from the official regulator.

60 Filings
2014 Period
2014 filings (60)
Filing Released Lang
Ethics Committee Approves Higher Dose ALT1103 Study 2 pages 121.7KB
Capital/Financing Update
2014-12-21 English
Company Update 2 pages 39.3KB
Capital/Financing Update
2014-12-08 English
Change of Director's Interest Notice (RM) 2 pages 22.3KB
Director's Dealing
2014-11-20 English
Change of Director's Interest Notice RM (amended) 2 pages 22.3KB
Director's Dealing
2014-11-20 English
Change of Director's Interest Notice (RM) 2 pages 22.2KB
Director's Dealing
2014-11-19 English
Change of Director's Interest Notice (RM) 2 pages 22.3KB
Director's Dealing
2014-11-16 English
Appendix 3B and Cleansing Notice 11 pages 211.9KB
Capital/Financing Update
2014-11-11 English
Change of Director's Interest Notice (RM) 2 pages 22.7KB
Director's Dealing
2014-11-11 English
Change of Director's Interest Notice (GM) 2 pages 23.1KB
Director's Dealing
2014-11-11 English
Change of Director's Interest Notice (CB) 2 pages 23.2KB
Director's Dealing
2014-11-11 English
Change of Director's Interest Notice (MD) 2 pages 23.2KB
Director's Dealing
2014-11-11 English
Share Purchase Plan Acceptances 1 page 21.9KB
Capital/Financing Update
2014-11-05 English
AGM Presentation 26 pages 3.8MB
AGM Information
2014-11-05 English
Results of Meeting 1 page 84.1KB
Declaration of Voting Results & Voting Rights Announcements
2014-11-05 English
Change of Director's Interest Notice (RM) 2 pages 44.2KB
Director's Dealing
2014-10-30 English
Appendix 4C - quarterly 5 pages 39.8KB
Interim / Quarterly Report
2014-10-29 English
Share Purchase Plan Closing Tomorrow 31 October 2014 1
Capital/Financing Update
2014-10-29 English
Trading Halt 1 page 136.2KB
Regulatory Filings
2014-10-23 English
Trading Halt Request 1 page 249.7KB
Regulatory Filings
2014-10-23 English
ATL1102 for MS FDA Response to Phase IIb Study Plans 1
Regulatory Filings
2014-10-23 English
Shareholder & Investor Presentation 61 pages 4.2MB
Investor Presentation
2014-10-19 English
ATL1103 for Acromegaly and ATL1102 for MS 1 page 20
Investor Presentation
2014-10-16 English
Receipt of $1.14 million R&D Tax Incentive payment 1
Capital/Financing Update
2014-10-14 English
World Leading Clinical Expert to Present to Shareholders 2 pages 187.7KB
Investor Presentation
2014-10-08 English
Share Purchase Plan Notice under ASIC CO 09/425 1
Capital/Financing Update
2014-10-06 English
Notice of Annual General Meeting and Annual Report 86 pages 1.4MB
AGM Information
2014-10-05 English
Share Purchase Plan 11 pages 94.4KB
Capital/Financing Update
2014-10-01 English
Placement Appendix 3B and Cleansing Notice 12 pages 442.0KB
Capital/Financing Update
2014-09-30 English
Share Purchase Plan Underwritten 1 page 22.2KB
Capital/Financing Update
2014-09-25 English
Placement and Share Purchase Plan 2 pages 73.1KB
Capital/Financing Update
2014-09-24 English
Trading Halt 2 pages 186.8KB
Capital/Financing Update
2014-09-22 English
ATL1102 Phase II MS trial results published in NEUROLOGY 2 pages 38.8KB
Regulatory Filings
2014-09-21 English
ATL1102 for MS further development plans 2 pages 28.5KB
Regulatory Filings
2014-09-15 English
BRR Interview - CEO Discusses ATL1103 Phase II Trial Results 2 pages 30.9KB
Regulatory Filings
2014-09-08 English
Ceasing to be a substantial holder 1 page 304.3KB
Regulatory Filings
2014-09-03 English
ATL1103 Phase II Trial - Successful Efficacy Results 7 pages 326.0KB
Regulatory Filings
2014-09-02 English
Trading Halt 2 pages 204.4KB
Regulatory Filings
2014-08-31 English
ATL1103 Acromegaly Phase II Trial Results 2 pages 31.8KB
Regulatory Filings
2014-08-27 English
Appendix 4E and Full Year Audited Statutory Accounts 81 pages 2.0MB
Annual Report
2014-08-24 English
Strategy Update - ATL1103 & ATL1102 2 pages 28.6KB
Capital/Financing Update
2014-08-18 English
Appendix 4C - quarterly 6 pages 57.6KB
Interim / Quarterly Report
2014-07-30 English
ATL1103 Acromegaly Phase II Trial Dosing Completed 2 pages 46.4KB
Capital/Financing Update
2014-07-28 English
ATL1102 for Stem Cell Mobilisation Trial Results 2 pages 31.5KB
Regulatory Filings
2014-07-22 English
Allowance of Canadian Patent on ATL1103 & Development Update 2 pages 35.2KB
Regulatory Filings
2014-07-06 English
Change in substantial holding 2 pages 107.7KB
Regulatory Filings
2014-07-01 English
Non-dilutive Funding Facility 1 page 20.3KB
Capital/Financing Update
2014-06-01 English
Investor Newsletter 6 pages 411.4KB
Investor Presentation
2014-05-22 English
Updated Investor Presentation 16 pages 677.5KB
Investor Presentation
2014-05-05 English
Appendix 4C - quarterly 5 pages 44.4KB
Interim / Quarterly Report
2014-04-28 English
ATL1102 for MS US Patent Allowance Extends IP Position 2 pages 44.9KB
Regulatory Filings
2014-04-06 English
ATL1102 for MS Toxicology Study Main Findings 1 pag
Regulatory Filings
2014-03-31 English
ATL1103 Acromegaly Phase II Trial Recruitment Completed 2 pages 73.2KB
Regulatory Filings
2014-03-20 English
ATL1102 for Stem Cell Mobilisation Trial Commencement 3 pages 82.1KB
Regulatory Filings
2014-03-17 English
ANP to Present at ROTH Capital Partners Conference 1
Investor Presentation
2014-03-06 English
Half Yearly Report and Accounts 28 pages 5.4MB
Interim / Quarterly Report
2014-02-23 English
Appendix 4C - quarterly 5 pages 60.1KB
Interim / Quarterly Report
2014-01-27 English
ATL1102 for Stem Cell Mobilisation Trial Approval 1
Regulatory Filings
2014-01-21 English
Appendix 3B 10 pages 215.1KB
Capital/Financing Update
2014-01-16 English
ANP Presentation at Biotech Showcase 2014 25 pages 1.0MB
Investor Presentation
2014-01-14 English
ANP Selected to Present at Biotech Showcase 2014 2 pages 30.3KB
Investor Presentation
2014-01-07 English